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Abstract
Aims. To determine the risk of dementia in patients with type 1 or type 2 diabetes and in
individuals with glycosylated haemoglobin, type A1C (HbA1c) of ⩾48 mmol/mol, which is
the diagnostic limit for diabetes.
Methods. We included the following cohorts: all incident diabetes cases aged 15 or above
registered in the National Diabetes Registry (NDR) from January 2000 through December
2012 (n = 148 036) and a reference population, adult participants from the Glostrup cohort
(n = 16 801), the ADDITION Study (n = 26 586) and Copenhagen Aging and Midlife
Biobank (CAMB) (n = 5408). Using these cohorts, we analysed if a diagnosis of type 1 or
type 2 diabetes in the NDR or HbA1c level of ⩾ 6.5% (48 mmol/mol) in the cohorts increased
risk of dementia in the Danish National Patient Registry or cognitive performance assessed by
the Intelligenz-Struktur-Test 2000R (IST2000R).
Results. A diagnosis of type 1 or type 2 diabetes in the NDR was associated with increased
risk of dementia diagnosed both before or after age 65 as well as across different subtypes
of dementia. Self-reported diabetes or high HbA1c levels were associated with lower cognitive
performance ( p = 0.004), while high HbA1c was associated with increased risk of dementia
(HR 1.94 (1.10–3.44) in the Glostrup cohort but not in the ADDITION Study (HR 0.96 (0.57–
1.61)).
Conclusions. Both type 1 and type 2 diabetes are associated with an increased risk of demen-
tia, while the importance of screening-detected elevated HbA1c remains less clear.
Introduction
Dementia is a broad category of diseases characterised by an irreversible decline of cognitive
function. Alzheimer’s disease is the most common cause of dementia, followed by vascular
dementia. Dementia is a leading cause of disability, and with an increasing elderly population
worldwide the prevalence of dementia is expected to increase (Umegaki, 2014). Lack of effect-
ive treatment calls for the identification of modifiable risk factors and strategies for prevention.
Type 2 diabetes has been associated with increased risk of developing all types of dementia, but
results have been conflicting and the association between diabetes and dementia is still
disputed.
So far, several meta-analyses have reported that diabetes increases risk of Alzheimer’s
Disease 1.5 times and vascular dementia 2.5 times (Cheng et al., 2012; Chatterjee et al.,
2016; Zhang et al., 2017). However, many of the included studies were limited by small sample
sizes with an insufficient number of outcomes or limiting controlling for clinical variables such
as cholesterol, body mass index (BMI), smoking status, or psychiatric comorbidity.
Furthermore, some studies even suggest that type 2 diabetes may not be a risk factor for
Alzheimer’s disease, or that it may only be a risk factor in a subgroup of patients (Heitner
and Dickson, 1997; Hassing et al., 2002; Smolina et al., 2015; Sherzai et al., 2016).
Importantly, most previous studies did not specifically characterise participants as type 1 or
type 2 diabetes. Only two studies have analysed risk of dementia in type 1 diabetes. In the
first study, the overall risk of dementia was increased with a relative risk of 1.65 (95% confi-
dence interval (CI) 1.61–1.68), however the risk of Alzheimer’s disease was lower (relative risk
1.10 (95% CI 1.05–1.15)) while the risk of vascular dementia was higher (relative risk 2.21
(95% CI 2.13–2.28)) (Smolina et al., 2015). The second study found a threefold increased
risk of dementia (Kuo et al., 2018), but the study was limited by few endpoints (n = 44 of
1077 type 1 diabetes patients) and did not distinguish between dementia types.
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Both hormonal and vascular mechanisms are suggested as
common pathological pathways between dementia and diabetes
(Nielsen et al., 2017; Arnold et al., 2018). Under normal circum-
stances, insulin serves many roles in the brain such as stimulating
the growth of neuronal cells and protection of apoptosis and oxi-
dative stress. Peripheral insulin anomalies are thought to cause a
decrease in brain insulin levels, disrupting these functions
(Blazquez et al., 2014). Hyperglycemia in itself is also shown to
have a toxic effect on neurons due to the production of advanced
glycation end products which cause oxidative damage and neur-
onal injury (Umegaki, 2014). A few studies have examined the
association between glucose levels and dementia and a cohort
study from the USA of 2961 men and women followed for 6.7
years suggested that higher glucose levels may be a risk factor
for dementia, even among persons without diabetes (Crane
et al., 2013).
Against this background, the aim of this study was to examine
if type 1 diabetes, type 2 diabetes, and dysglycemia were asso-
ciated with lower cognitive performance and increased risk of
dementia. In nationwide registers and population-based cohorts,
we tested the following hypotheses:
(1) Type 1 and type 2 diabetes are associated with increased risk
of dementia after controlling for sociodemographic factors
and somatic and psychiatric comorbidity.
(2) HbA1c of 48 mmol/mol (6.5%) (which is the limit for dia-
betes) is associated with increased risk of dementia after con-
trolling for lifestyle-related covariables.
(3) Individuals with HbA1c of 48 mmol/mol (6.5%) and/or self-
reported diabetes have lower cognitive performance than
individuals with HbA1c of 48 mmol/mol (6.5%) and no self-
reported diabetes after controlling for lifestyle-related covari-
ables and inflammatory markers.
Material and methods
Study population
We used information from four cohorts: A nationwide, register-
based cohort with all diabetes cases registered in the National
Diabetes Register (NDR) and a matched reference population
(Carstensen et al., 2011), the Glostrup cohorts (Osler et al.,
2011), the ADDITION cohort (Lauritzen et al., 2000), and the
Copenhagen Aging and Midlife Biobank (CAMB) (Avlund
et al., 2014). An overview of the four cohorts is given in Table 1.
The nationwide, register-based cohort was based on informa-
tion on all patients aged 15 or above registered with incident type
1 or type 2 diabetes in NDR between 1 January 2000 and 31
December 2012. The NDR is based on a validated algorithm
which combines information on diabetes ascertained by physi-
cian’s diagnosis (International Classification of Disease 10
(ICD10) codes DE10–14, DH36.0, DO24) in the Danish
National Patients Registry, prescriptions of antidiabetic medica-
tion in the Danish Prescription Register, and measures of blood
glucose or referrals to feet therapists from the National Health
Insurance Service Register (Carstensen et al., 2011). A reference
population was established by 1:1 matching on gender, age, and
municipality on time of diabetes diagnosis using information
from the Civil Registration System (Pedersen, 2011). If diabetes
type (type 1 diabetes or type 2 diabetes) was unclear (n = 10
303), use of oral antidiabetic medication and/or age at diagnosis
>35 was used to define type 2 diabetes. In total 127 369 persons
with type 2 diabetes and 20 664 patients with type 1 diabetes
and similar numbers in the reference populations were included.
A flow chart of individuals included is shown in Supplementary
Fig. 1.
In this study, the Glostrup cohort consisted of a pooling of
the Inter99, Health2006 and the Danish study of Functional
Disorders (DanFunD). Inter99 was a population-based primary
intervention study and included 6784 randomly sampled indivi-
duals aged 30–60 years who participated (participation rate:
52.5%) in a health examination between 1999 and 2001
(Jorgensen et al., 2003). The Health2006 cohort included 3471
randomly sampled individuals, aged 18–69 years, who were exam-
ined (participation rate: 44.7%) between 2006 and 2009 (Thuesen
et al., 2014). DanFunD included 6837 randomly selected indivi-
duals, aged 18–72 years (participation rate: 29.5%) who were
examined between 2012 and 2014 (Dantoft et al., 2017). A total
of 16 801 cohort members had measurements of HbA1c. Of
these, 21 had dementia before study entry leaving 16 780 for
analysis.
The ADDITION study (The Anglo-Danish-Dutch Study of
Intensive Treatment in People with Screen Detected Diabetes in
Primary Care) was initiated in 1999 and included individuals at
risk of diabetes but without a diagnosis of diabetes. In
ADDITION-Denmark a total of 163 189 men and women aged
40–69 years received a risk score questionnaire and of these 28
035 with a risk score of ⩾5 visited their family doctor and were
included in ADDITION (Lauritzen et al., 2011). A total of 26
586 individuals had measurements of HbA1c and as 50 had
dementia before study entry, this left us 26 536 individuals avail-
able for analysis.
Finally, CAMB was based on three cohorts: the Metropolit
study, the Danish Longitudinal Study of Work, Unemployment
and Health cohort, and the Copenhagen Perinatal Birth Cohort
(Avlund et al., 2014). A total of 5575 participants aged 49–53
years were assessed with a test of cognitive performance and
blood sampling in a midlife follow-up from 2009 to 2011 with
a response rate of 30%. After exclusion of 167 individuals without
information on either cognitive performance, self-reported dia-
betes or HbA1c, 5408 individuals were left for analysis.
Exposures
In the nationwide register-based study, diabetes was defined by
the algorithm described above. In the three other cohorts, we
defined diabetes as having baseline HbA1c of 48 mmol/mol
(6.5%). In CAMB, diabetes was also defined by self-reported
diabetes.
HbA1c measurements
In Inter99 Glycosylated Haemoglobin, type A1C (HbA1c) was
assayed by ion-exchange high-performance liquid chromatog-
raphy technique (HPLC) (Bio-Rad variant). In Health2006,
HbA1c was measured using HPLC on a Tosoh G8 Analyzer. In
DanFunD, HbA1c was measured using the VITROS Chemistry
Products d%A1c Reagent Kit utilising a quantitative turbidimetric
inhibition immunoassay until July 2013 and from July 2013 using
the HPLC technique on a Tosoh G8 Analyzer. Levels of HbA1c
were similar in all three cohorts. In the ADDITION study,
HbA1c was similarly measured using ion-exchange HPLC
(Tosoh Bioscience, Redditch, UK) and in the CAMB cohort
using ion-exchange HPLC on a Waters 625 LC system together
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with a Waters photo-diode-array detector model 996 and WISP
717 autosampler for automatic injection of the samples.
All measurements of HbA1c were DCCT (Diabetes Control
and Complications Trial) aligned but were converted to IFCC
(International Federation of Clinical Chemistry) units before
analysis.
Outcomes
Dementia was ascertained by physician’s diagnosis in the Danish
National Patient Registry using ICD10 codes F00-F03 and G30–
31 (Supplementary Table 1). In the register-based cohort, demen-
tia was subdivided into Alzheimer’s dementia, vascular dementia,
or other dementia based on ICD10 codes shown in
Supplementary Table 1. The validity of dementia diagnoses
obtained from this register has been assessed in two independent
studies of patients admitted in 2003 (Phung et al., 2007), and
2008 (Thygesen et al., 2011; Salem et al., 2012). They revealed
that for diagnosis defined by ICD-10, 70% (Salem et al., 2012)
and 83% (Phung et al., 2007) of dementia cases diagnosed by
an external rater confirmed the diagnosis recorded in the register
(Thygesen et al., 2011) with the lowest validity in younger popu-
lations and for vascular dementia.
In CAMB, we used cognitive performance assessed by the
Intelligenz-Struktur-Test 2000R (IST2000R) translated into
Danish by Hogrefe Publishers (Amthauer, 2000). Three subtests
of the IST2000R are included in CAMB: Sentence completion,
verbal analogies and number series (Avlund et al., 2014).
Covariables
We included a number of covariables assumed to be associated
with diabetes and the risk of dementia. Covariables are listed in
Supplementary Table 2. In the nationwide register-based cohort,
the Glostrup cohorts, and in ADDITION, education was cate-
gorised as basic education (7–9 grade of obligatory schooling),
medium education (high school degree/vocational), higher educa-
tion (more than high school degree) or missing based on data
Table 1. Baseline characteristics of the National Diabetes Register cohort
Reference DM1 DM2
Number (n) 144 807 20 261 125 520
Basic variables
Age in years, mean (range) 60.2 (15–104) 52.4 (15–102) 61.7 (15–104)
Men, n (%) 81 333 (56) 10 887 (54) 70 806 (56)
Education, n (%)
Basic education 51 839 (36) 8160 (40) 53 733 (43)
Medium education 57 367 (40) 7599 (38) 47 547 (38)
Long education 24 629 (17) 2386 (12) 13 752 (11)
Missing 10 972 (8) 2116 (10) 10 488 (8)
Marital status, n (%)
Married 81 718 (56) 8777 (43) 70 340 (56)
Unmarried 21 910 (15) 6364 (31) 17 405 (14)
Divorced 21 075 (15) 2346 (12) 18 699 (15)
Widow/widower 19 296 (13) 2364 (12) 18 411 (15)
Missing 808 (0.6) 410 (2) 665 (0.5)
Illness variables
Ischemic heart disease, n (%) 8327 (6) 2591 (13) 18 237 (15)
Cerebrovascular disease, n (%) 5000 (3) 1930 (10) 8463 (7)
Cardiovascular medication, n (%) 26 980 (19) 5049 (25) 42 374 (34)
Hypertension, n (%) 48 221 (33) 9653 (48) 78 066 (62)
Obesity, n (%) 5376 (4) 2124 (10) 18 658 (15)
Hypercholesterolemia, n (%) 17 272 (12) 3785 (19) 39 365 (31)
Infection, n (%) 18 692 (13) 5672 (28) 28 725 (23)
Chronic obstructive pulmonary disease, n (%) 15 344 (11) 2985 (15) 20 992 (17)
Inflammatory disease, n (%) 4416 (3) 1258 (6) 7119 (6)
Alcohol use disorder, n (%) 2784 (2) 1313 (6) 4505 (4)
Major depression, n (%) 23 226 (16) 4034 (20) 26 648 (21)
DM1, Diabetes Mellitus type 1; DM2, Diabetes Mellitus type 2.
Based on patients with diabetes from the National Diabetes Register and a non-diabetic reference group from the Civil Registration System. Individuals with previous dementia are excluded.
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from the Integrated Database for Labor Market Research. In
CAMB, education was based on self-reported education and cate-
gorised into basic education, skilled worker, short/medium educa-
tion, long education or other education. Marital status was based
on data from the Danish Civil Registration System and categorised
as married, unmarried, divorced, or widow/widower. In CAMB,
we only had information on whether the participant lived alone
or not. Somatic and psychiatric comorbidity in the register-based
cohort, the Glostrup cohorts and ADDITION were based on
either hospitalisation and/or medication registered in the
National Patient Registry and the Danish Prescription Register 5
years preceding inclusion of the study. The ICD10 and ATC
codes are shown in Supplementary Table 1. All clinical variables
and blood tests were measured at the first visit. In the three
population-based cohorts, each participant underwent a physical
examination by trained staff following standard operation proce-
dures. BMI (kg/m2) was defined as weight in kilograms divided by
height in meters squared. In CAMB body fat was measured using a
Tanita Multi-Frequency Body Composition Analyzer MC-180MA
after standard instructions from the manufacturer. In CAMB,
C-reactive protein (CRP) was measured using a high sensitive
assay using latex-enhanced turbidimetry (Roche/Hitachi), using
assays Tina Quant, Roche Diagnostics GmbH, Mannheim,
Germany. Interleukin (IL) 6 and IL-10 were measured by an
electro-chemiluminescence multiplex system on Sector 2400
Imager from Meso Scale Discovery (Gaithersburg, USA).
Statistical analyses
Stata version 14.2 (StataCorp, College Station, TX) was used for
statistical analysis. Missing data (<5% for each variable), assumed
to be missing at random, were imputed using age, sex, and marital
status. More information on missing data is provided in
Supplementary Information.
Hypothesis 1 was tested using Cox proportional hazard regres-
sion models with age as the underlying time scale. Study entry
was the date of inclusion in the NDR or the corresponding date
for the reference population. End of follow-up was time of
dementia, emigration, or death in the Civil Registration System,
or end of follow-up (11 May 2018), whichever came first.
Individuals (n = 5433) with a diagnosis of dementia or the use
of dementia medication before study entry were excluded before
analysis. Due to the interaction of age at dementia diagnosis,
the results were stratified into early dementia (<65 years of age)
and late dementia (⩾65 years of age). In analyses of early demen-
tia, follow-up was ended at age 65 if individuals were not censored
before. In the analyses of late dementia, study entry was at age 65
or later (if the inclusion date into the NDR was after age 65), and
consequently, individuals who were younger than 65 years old
during follow-up were not included. The proportional hazards
assumption was tested graphically by plotting –log(-log(survival))
v. log(follow-up time) and no major violations were found after
stratification on age at diagnosis. Potential interaction between
diabetes and sex on risk of dementia was tested for by introducing
a multiplicative interaction term (diabetes × sex) into the model
and comparing the models using a likelihood ratio test.
Covariables were adjusted for as shown in Table 1 and
Supplementary Table 2. Diabetes might be diagnosed during test-
ing for dementia, to account for detection bias we delayed
follow-up for 1 year using the stsplit option in STATA to divide
the follow-up time into 0–1 year and above as done in previous
studies (Katon et al., 2015). We further examined dementia
subtypes. In these analyses, all individuals with any dementia
diagnosis or medication before study entry were excluded. If indi-
viduals had more dementia diagnoses of different subtypes at dif-
ferent times, we followed individuals until the first dementia
diagnosis regardless of which type it was, i.e. only allowing indi-
viduals to have one dementia diagnosis. A total of 804 individuals
had a diagnosis of Alzheimer’s dementia and ‘other dementia’ at
the same time and were classified as having Alzheimer’s demen-
tia. However, as well as examining only the first subtype diagnosis
which may be less valid (e.g. unspecified dementia), in supple-
mentary analyses we also made subtype analyses in which we fol-
lowed individuals until only the specific dementia subtype, thus
allowing individuals to have several different dementia subtypes.
For the second hypothesis, the Glostrup cohorts and
ADDITION were analysed separately using a Cox model as
described above. Study entry was the day of study participation.
A total of 21 individuals in the Glostrup cohorts and 50 indivi-
duals in ADDITION diagnosed with dementia or a purchase of
dementia medication before study entry were excluded from the
analyses. When the proportional hazards assumption was tested
no violations were found. Due to a limited number of outcomes,
multivariable adjustment was limited to adjustment for age, sex,
education, smoking status, physical activity, BMI and depression.
Finally, the third hypothesis was tested in CAMB using
multiple regression models to estimate the correlation between
HbA1c level and cognitive performance with adjustment as
shown in Supplementary Table 2.
Results
Risk of dementia in patients with type 1 diabetes or type 2
diabetes
Baseline characteristics of the 20 261 individuals with type 1 dia-
betes and 125 520 individuals with type 2 diabetes and their
respective reference population in the nationwide cohort are
shown in Table 1. Median follow-up was 11.3 years (range 0–18
years) for analyses of early dementia (before age 65) and 9.9
years for analyses of late dementia (after age 65). The absolute
rate of early dementia was quite low. A total of 88 (0.6%) indivi-
duals with type 1 diabetes and 609 (0.8%) with type 2 diabetes
were diagnosed with early dementia compared to 344 (0.4%) in
the reference population, while the corresponding numbers for
late dementia were 597 (6.4%), 5989 (6.8%) and 5913 (6.0%).
Type 1 diabetes and type 2 diabetes were associated with
increased risk of both early and late dementia. For late dementia,
the rates among patients with type 1 and type 2 diabetes were
slightly lower for Alzheimer’s dementia while slightly higher for
vascular dementia and other dementia and for all subtypes,
rates had slightly wider confidence intervals for type 1 diabetes
due to the lower number of outcomes (Fig. 1). Type 1 diabetes
was associated with a HR of 1.18 (1.08–1.29) for all-cause demen-
tia after multivariable adjustment while the corresponding HR for
type 2 diabetes was 1.22 (1.17–1.26). In the subtype analyses
which allowed for several subtypes of dementia, the estimates
were similar but with more narrow confidence intervals due to
the slightly higher number of endpoints (Supplementary Fig. 2).
We found no interaction with sex (data not shown). The corre-
sponding HRs for early depression before age 65 were slightly
higher and is shown in Supplementary Table 3 and 4. The rates
of dementia within the first year or after the first year after a dia-
betes diagnosis did not suggest the presence of detection bias
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(Supplementary Table 5). When we examined dementia subtypes,
the analyses of early Alzheimer’s dementia and early vascular
dementia were hampered by an insufficient number of dementia
outcomes.
HbA1c levels and risk of dementia
After exclusion of individuals with a previous depression (N = 21
in the Glostrup cohorts and N = 50 in ADDITION), a total of
3.8% (n = 638) had a HbA1c of 48 mmol/mol (corresponds to
HbA1c of 6.5%) in the Glostrup cohorts, while in ADDITION,
the corresponding proportion was 3.0% (n = 789). Baseline char-
acteristics are shown in Supplementary Table 6 and 7. During a
median follow-up of 9.8 years (range 0.01–36) in the Glostrup
cohorts and of 12.7 years (range 0.2–14.8) in ADDITION, 112
and 614 developed dementia. In the Glostrup cohorts, HbA1c
of 48 mmol/mol was associated with an increased risk of demen-
tia with a HRage and sex adjusted of 2.12 (95% CI 1.22–3.67) which
was attenuated to 1.94 (1.10–3.44) after multivariable adjustment
for age, sex, education, physical activity, BMI and depression
(Fig. 2). In ADDITION, HbA1c was not associated with dementia
before or after multivariable adjustment (Fig. 3).
HbA1c levels and cognitive performance
In the CAMB cohort, 239 (4%) was defined as having diabetes
based on self-reports or HbA1c of 48 mmol/mol (6.5%).
Characteristics are shown in Supplementary Table 8. Individuals
with diabetes had lower cognitive performance scores as com-
pared to individuals without diabetes ( p = 5 × 10−6) and the dif-
ference remained significant after multivariable adjustment ( p =
0.004) (Fig. 4).
Discussion
Our nationwide register-based cohort based on all patients diag-
nosed with diabetes in Denmark between 2000 and 2012 showed
that both type 1 diabetes and type 2 diabetes patients had increased
risk of any dementia. The highest risk (up to a 30% increase) was
for dementia diagnosed before age 65. In patients with type 1 dia-
betes, we found no increase in the risk of Alzheimer’s Disease or
vascular dementia, while patients with type 2 diabetes had
increased risk of both vascular dementia and Alzheimer’s
Disease. Further, in the population-based cohorts HbA1c-defined
diabetes was associated with lower cognitive performance, and in
one cohort with increased dementia risk, but not in the other.
Fig. 1. Prospective associations between diabetes type 1 and 2 and dementia above age 65 in the nationwide study. Multivariable adjustment was for age, sex,
marital status, education, register-based ischemic heart disease, cerebrovascular disease, vascular disease medication, hypertension, obesity, hypercholesterol-
emia, infections, chronic obstructive pulmonary disease, inflammatory diseases, depression and alcohol use disorders. HR, hazard ratio; CI, confidence interval.
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Previous studies and meta-analyses on the association
between type 2 diabetes and dementia have reported much
stronger associations, but their results have mainly been driven
by two large cohorts from Taiwan (Wang et al., 2012) and
South Korea (Kimm et al., 2011). The strength of an association
depends on the distribution of other component causes in the
population (Rothman, 1976), and Asian populations may have
a different risk profile compared to ours (Zhang et al., 2017).
Our findings are in line with a Canadian study showing a 16%
increased risk of dementia in 225 045 seniors with diabetes
(Haroon et al., 2015). Also, a previous Danish study of 223
174 diabetes patients examining the combined risk of diabetes
and depression on dementia, found that diabetes alone increased
risk of dementia 10% after multiple adjustments (Katon et al.,
2015). However, none of the studies categorised diabetes patients
into type 1 or 2.
Fig. 2. Prospective association between HbA1c and dementia in the combined Glostrup cohorts. Based on 16 780 individuals from the combined Glostrup cohorts.
A total of 21 individuals with dementia before study entry were excluded before analysis. Multivariable adjustment was for age, sex, cohort, education, marital
status, smoking status, physical activity, body mass index, systolic blood pressure, total cholesterol and register-based ischemic heart disease, cerebrovascular
disease and statin use.
Fig. 3. Prospective association between HbA1c and dementia in the Addition Study. Based on 26 536 individuals from the Addition study. A total of 50 individuals
with dementia before study entry were excluded before analysis. Multivariable adjustment was for age, sex, education, marital status, smoking status, physical
activity, body mass index, systolic blood pressure, and register-based ischemic heart disease, cerebrovascular disease and depression. HR, hazard ratio; CI, con-
fidence interval.
Fig. 4. Cross-sectional association between diabetes and cognitive performance on the IST2000R in the CAMB cohort. Based on 5408 individuals in the Copenhagen
Aging and Midlife Biobank (CAMB). Diabetes was based on self-reports or a HbA1c ⩾ 48 mmol/mol. IST2000R = Intelligenz-Struktur-Test 2000R. Multifactorially
adjustment was for age, sex, education, living alone, alcohol, smoking, high sensitive C-reactive protein, interleukin 6, interleukin 10 and body fat percentage.
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Our findings for HbA1c were conflicting. In the Glostrup
cohorts, HbA1c of 48 mmol/mol (6.5%) increased risk of demen-
tia, but in ADDITION no association between HbA1c and
dementia was found. Two previous studies found that HbA1c of
53 mmol/mol (7%) or more was associated with increased risk
of dementia, while a diagnosis of diabetes or self-reported dia-
betes was not associated with dementia (Gao et al., 2008;
Ramirez et al., 2015). However, the studies only had 58 and 67
dementia cases, respectively. A larger cohort study of 232 patients
with diabetes and 1835 patients without diabetes found a relation-
ship between sustained elevated glucose levels and dementia risk
that was independent of diabetes diagnosis (Crane et al., 2013).
One possible explanation for the lack of association between
HbA1c and dementia in ADDITION could be that study partici-
pants were a part of an intervention study receiving intensive care
including educational meetings with family physicians and nurses
to discuss treatment targets, and lifestyle advice, and more inten-
sive treatment of risk factors such as blood pressure and choles-
terol or routine care. After 5 years of follow up, the intensive
group had slightly but significantly lower HbA1c, cholesterol
and blood pressure (Griffin et al., 2011). Participants in Inter99
(n = 6774) in the Glostrup cohorts were also enrolled in an inter-
vention and received lifestyle counselling on smoking cessation or
physical activity/diet over 6 months or referral to their general
practitioner. However, in Inter99, after 10 years the groups had
an equal risk of ischaemic heart disease, stroke, and mortality
(Jorgensen et al., 2014). Unfortunately, there was no follow-up
on HbA1c or other clinical variables. Therefore, the results in
ADDITION could suggest that tight metabolic control lowers
the risk of dementia in patients with diabetes. However, until
now other studies investigating this have failed to find intensive
glycemic control to be associated with a lower risk of dementia
(Advance Management Committee, 2001) or better cognitive out-
come (Areosa Sastre et al., 2017).
Finally, we found that self-reported diabetes and/or HbA1c of
48 mmol/mol (6.5%) or above was associated with lower cognitive
performance on the IST2000R test after controlling for markers of
inflammation. This is in line with previous studies analysing
HbA1c levels and cognitive dysfunction (Cukierman-Yaffe et al.,
2009; Avadhani et al., 2015). Inflammation may influence cogni-
tion and two studies even found that metabolic syndrome was
associated with cognitive dysfunction only in patients with high
inflammation (Yaffe et al., 2004; Dik et al., 2007).
Strengths and limitations: We tested dementia risk in both a
large nationwide register-based cohort and two independent
cohorts with information on several covariables including educa-
tion and comorbidity and additionally clinical covariables in the
population-based cohorts including lifestyle factors, BMI, blood
pressure and cholesterol level. It may limit our results, especially
in the Glostrup cohorts that participation rates were relatively
low. However, the nationwide register-based cohort covers all
individuals diagnosed with diabetes and we had a nearly complete
follow-up for hospital diagnosis and prescription records which
reduces loss to follow-up and any associated bias. Furthermore,
despite a large sample size in the Glostrup, ADDITION and
CAMB cohorts, numbers of endpoints were relatively small and
consequently, we lack power to explore repeated measures of
HbA1c. However, in the nationwide study, we had a relatively
large number of endpoints due to the large number of individuals
included. Unfortunately, we did not have clinical covariables such
as BMI, blood pressure, cholesterol level or inflammatory markers
available in this study, which we had in the population-based
cohorts. We did not include antidiabetic medication in our ana-
lysis since this was not regarded as confounders but potential
mediators of the association. Median follow-up time in all cohorts
was relatively short (9.8–12.7 years), limiting our results as mean
age at end of follow-up ranged from 56 to 57 years in type 1 dia-
betes and their reference population and 71–72 years in type 2
diabetes and their reference population. In CAMB, we only had
one measurement of cognitive performance and could not evalu-
ate changes over time. Also, we only had three subtests of
IST2000R which were primarily testing crystalised verbal cogni-
tive ability, which may not be a sensitive measure of midlife cog-
nitive changes (Avlund et al., 2014). Overall, the validity of
dementia in the National Patient Register is high, however,
Alzheimer’s Disease may be underdiagnosed, and vascular
dementia has substantially lower validity (Phung et al., 2007).
We found a high proportion of dementia classified as other
dementia. More than 91% of the dementia cases in this category
was diagnosed ‘unspecified dementia’ (DF03 and G31.9) (data not
shown) while the rest was Lewy-body dementia and fronto-
temporal dementia. A validation study of dementia diagnosis in
the Danish registers showed that a substantial number of cases
registered as unspecified dementia is, in reality, Alzheimer’s
Disease (Phung et al., 2007). In our study, these cases may have
provided the extra power to detect a significantly increased risk
of Alzheimer’s Disease in type 1 diabetes or further accentuate
the risk of Alzheimer’s Disease in type 2 diabetes.
Based on nationwide data on a large diabetes population and
previous evidence, we conclude that both type 1 diabetes and
type 2 diabetes are associated with a higher risk of dementia
and a lower cognitive performance, while the importance of single
elevated HbA1c measure could be questioned.
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